Search Results
Your search for all items matches 32928 pages
Showing 151 - 200W. Kimryn Rathmell, MD, PhD, Selected as 17th Director of the NCI
W. Kimryn Rathmell, MD, PhD, took the helm as the 17th Director of the National Cancer Institute (NCI), part of the National Institutes of Health (NIH), on December 18, 2023. A renowned kidney cancer expert and influential leader in cancer research and patient care, Dr. Rathmell was selected by...
Liposomal Irinotecan in First-Line Treatment of Metastatic Pancreatic Adenocarcinoma
On February 13, 2024, the U.S. Food and Drug Administration approved liposomal irinotecan (Onivyde) for use with oxaliplatin, fluorouracil, and leucovorin in the first-line treatment of metastatic pancreatic adenocarcinoma.1 Supporting Efficacy Data Approval was based on the open-label NAPOLI 3...
Brachytherapy Boost May Decrease the Duration of Androgen-Deprivation Therapy for High-Risk Prostate Cancer
The optimal management of high-risk prostate cancer remains a topic of ongoing investigation. The quest for therapy that maximizes cancer control while minimizing toxicity is constant. Over the past decade, there has been mounting evidence that the addition of a brachytherapy boost to external-beam ...
CAR T-Cell Therapy Complications: Comparison of Three Testing Modalities
Magnetic resonance imaging (MRI) and lumbar puncture may not always be necessary for diagnosing and managing a serious neurologic complication associated with chimeric antigen receptor (CAR) T-cell therapy, according to a new study published by Mauget et al in Blood Advances. Findings further...
Effect of HER2 Gene–Expression Levels on Outcomes in Metastatic Colorectal Cancer
As reported in the Journal of Clinical Oncology by Battaglin et al, an analysis from the phase III CALGB/SWOG 80405 trial of first-line chemotherapy plus bevacizumab or cetuximab in patients with metastatic colorectal cancer showed differences in outcomes according to HER2 gene–expression status....
Localized Prostate Cancer: Association of PSA Nadir Within 6 Months of Radiotherapy With Outcomes
In a study reported in the Journal of Clinical Oncology, Kwak et al found that prostate-specific antigen (PSA) levels ≥ 0.1 ng/mL within 6 months after completion of radiotherapy were prognostic for poorer outcomes in patients with localized prostate cancer who did or did not also receive...
Cancer Care Providers Urge President Biden to Make Health Care a State of the Union Priority
In a news release issued by ASCO earlier this month, the society reported that The Association for Clinical Oncology (ASCO) was calling on President Biden to continue to prioritize access to high-quality, equitable cancer care in his State of the Union address. Specifically, the cancer care...
Adjuvant Pembrolizumab: A New Option for High-Risk Muscle-Invasive Urothelial Cancer
Adjuvant use of the PD-1 inhibitor pembrolizumab achieved a statistically significant and clinically meaningful improvement in disease-free survival in patients with high-risk muscle-invasive urothelial carcinoma vs observation after surgical resection, according to an interim analysis of the phase ...
Use of Combination Immunotherapy Before Lung Cancer Surgery
Combination immunotherapy with the anti–PD-L1 monoclonal antibody durvalumab and other novel agents seemed to outperform durvalumab alone in the neoadjuvant setting for early-stage non–small cell lung cancer (NSCLC), according to researchers from The University of Texas MD Anderson Cancer Center,...
Mantle Cell Lymphoma: Front-Line Therapy
“The practice of medicine is an art, not a trade….” —Sir William Osler Mantle cell lymphoma (MCL) accounts for approximately 5% to 7% of all lymphomas; the median age of patients with MCL is between 60 and 70 years. This lymphoma is generally considered incurable. Median survival in retrospective...
Strategies for Cardiovascular Risk Mitigation and Monitoring in Patients With CLL
With a 5-year overall survival of close to 90% in chronic lymphocytic leukemia (CLL), there have been large treatment shifts over the past decade in this disease, which now includes “more disciplines than it did before,” commented medical oncologist Danielle Shafer, DO, of Inova Schar Cancer...
Cabozantinib Plus Atezolizumab Improves Progression-Free Survival
The combination of the tyrosine kinase inhibitor cabozantinib (multiple targets, including MET, AXL, VEGFR2, RET, and FLT ) plus the monoclonal antibody atezolizumab achieved statistically significant improvement in progression-free survival compared with second-line novel hormonal therapy in...
Repotrectinib for ROS1 Fusion–Positive Advanced NSCLC
On November 15, 2023, repotrectinib (Augtyro) was approved for locally advanced or metastatic ROS1 fusion–positive non–small cell lung cancer (NSCLC).1 This is the first U.S. Food and Drug Administration approval that includes patients with ROS1-positive NSCLC who have previously received a ROS1...
Osimertinib With Chemotherapy for EGFR-Mutated NSCLC
On February 16, 2024, osimertinib (Tagrisso) was approved by the U.S. Food and Drug Administraton (FDA) with pemetrexed and platinum-based chemotherapy for patients with locally advanced or metastatic non–small cell lung cancer (NSCLC) with tumors having EGFR exon 19 deletions or exon 21 L858R...
Risks of Cardiovascular Disease in Patients Receiving Therapies for Lung Cancer
Managing patients with lung cancer in the current era of an increasing array of systemic treatments has become a complex balancing act of trying to improve outcomes and survival from a cancer perspective while taking the necessary treatment and monitoring steps for cardioprotection. With few...
Avelumab Plus Axitinib in Mismatch Repair–Proficient Recurrent or Persistent Endometrial Cancer
The combination of avelumab and axitinib may be effective in patients with mismatch repair–proficient recurrent or persistent endometrial cancer, according to new findings presented by Lee et al at the Society of Gynecologic Oncology’s (SGO) 2024 Annual Meeting on Women’s Cancer. Background...
Liquid Biopsy May Help Predict Outcomes in Patients With Gastroesophageal Cancers Following Immunotherapy
Monitoring circulating tumor DNA (ctDNA) levels with liquid biopsies could help physicians accurately assess treatment responses and predict future prognoses in patients with operable esophageal or gastroesophageal junction cancer receiving an immunotherapy doublet, according to a recent study...
Mansoor R. Mirza, MD, on Endometrial Cancer: Update on Combination Regimen of Dostarlimab, Chemotherapy, and Niraparib
Mansoor R. Mirza, MD, of Copenhagen University Hospital, discusses follow-up results from the RUBY trial, showing that, for patients with primary advanced or recurrent endometrial cancer, dostarlimab-gxly plus chemotherapy followed by dostarlimab-gxly plus niraparib improved progression-free...
Brian M. Slomovitz, MD, on Cervical Cancer: Update on Tisotumab Vedotin vs Chemotherapy
Brian M. Slomovitz, MD, of Mount Sinai Medical Center, Miami Beach, discusses additional phase III data from the innovaTV 301 trial, which showed that in patients with previously treated recurrent or metastatic cervical cancer, tisotumab vedotin-tftv was more efficacious than chemotherapy as...
FDA Grants Accelerated Approval to Ponatinib With Chemotherapy for Newly Diagnosed Philadelphia Chromosome–Positive ALL
On March 19, the U.S. Food and Drug Administration (FDA) granted accelerated approval to the multitarget kinase inhibitor (Iclusig) with chemotherapy for adult patients with newly diagnosed Philadelphia chromosome–positive acute lymphoblastic leukemia (ALL). PhALLCON Efficacy was evaluated in...
Next-Generation Multitarget Stool DNA Test for Colorectal Cancer Screening
In the BLUE-C study—reported in The New England Journal of Medicine—Imperiale et al found that a next-generation multitarget stool DNA test showed high sensitivity for colorectal cancer and high specificity for advanced neoplasia compared with colonoscopy screening. Study Details The U.S....
Adjuvant Pembrolizumab in Resected Stage IIB or IIC Melanoma
As reported in the Journal of Clinical Oncology by Jason J. Luke, MD, FACP, and colleagues, the final prespecified analysis of distant metastasis–free survival in the phase III KEYNOTE-716 trial showed continued benefit with adjuvant pembrolizumab vs placebo in patients with resected stage IIB or...
Lillian L. Siu, MD, FRCPC, FASCO, FAACR, Named 2024–2025 AACR President-Elect
The American Association for Cancer Research (AACR) announced that its members have elected Lillian L. Siu, MD, FRCPC, FASCO, FAACR, as the 2024–2025 President-Elect of the AACR. Professional and Research Background Dr. Siu currently serves as Professor of Medicine at the University of Toronto; as ...
Hormonal Therapy Plus SBRT for Advanced Prostate Cancer
Treatment with a short course of intensified hormonal therapy in combination with metastasis-directed stereotactic body radiation therapy (SBRT) may be safe and effective in patients with oligorecurrent and metastatic prostate cancer, according to a recent study published by Nikitas et al in...
Performance of cfDNA Blood-Based Test for Colorectal Cancer Screening
In the ECLIPSE study—reported in The New England Journal of Medicine—Chung et al found that a cell-free DNA (cfDNA) blood-based test had high sensitivity for colorectal cancer and high specificity for advanced neoplasia in colorectal cancer screening compared with colonoscopy. Study Details The...
Marcin R. Dzienis, MBBS, on Update on Pembrolizumab, Carboplatin, and Paclitaxel in HNSCC
Marcin R. Dzienis, MBBS, of Australia’s Gold Coast University Hospital, discusses the final analysis of KEYNOTE-B10, a phase IV study in which patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) received a first-line combination regimen of pembrolizumab plus...
Durvalumab-Based Regimens Improve Response Over Chemotherapy Alone in pMMR Advanced Endometrial Cancer
Latest analysis of the results from the phase III DUO-E trial showed durvalumab plus platinum-based chemotherapy followed by durvalumab plus olaparib demonstrated an improvement in multiple key secondary efficacy endpoints, particularly in patients with mismatch repair–proficient (pMMR) advanced or ...
Localized or Advanced Prostate Cancer: Short- or Longer-Term Relugolix Plus Radiotherapy
In an analysis reported in JAMA Oncology, Daniel E. Spratt, MD, and colleagues found that treatment with relugolix was associated with rapid achievement of sustained castration in patients with localized or advanced prostate cancer who were also receiving radiotherapy. Study Details The analysis...
ChatGPT May Accurately Answer Common Patient Questions Regarding Gynecologic Cancer
The artificial intelligence (AI)-based chatbot ChatGPT version 3.4 may correctly answer a majority of the common genetic counseling questions related to gynecologic oncology, according to new findings presented by Patel et al at the Society of Gynecologic Oncology’s (SGO) 2024 Annual Meeting on...
Exploring the Genetic Link Between Colorectal Cancer and Meat Consumption
Researchers have identified two genetic markers that may illuminate the association between red and/or processed meat consumption and the risk of colorectal cancer, according to a novel study published by Stern et al in Cancer Epidemiology, Biomarkers & Prevention. Background Previous studies...
SABR for Patients With Primary Kidney Cancer Not Undergoing Resection
In a phase II study (FASTRACK II) reported in The Lancet Oncology, Shankar Siva, MBBS, PhD, and colleagues found that stereotactic ablative body radiotherapy (SABR) was effective in patients with primary kidney cancer who did not undergo resection. Study Details Seventy patients were enrolled in...
H pylori Infection: Risk of Colorectal Cancer and Colorectal Cancer–Related Mortality
In a study among U.S. veterans reported in the Journal of Clinical Oncology, Shah et al found that Helicobacter pylori infection was associated with an increased risk of colorectal cancer and cancer-related death; additionally, treated H pylori infection was associated with reduced cancer incidence ...
Accelerated Approval Granted to First CAR T-Cell Therapy for Relapsed or Refractory CLL/SLL
On March 14, the U.S. Food and Drug Administration (FDA) granted accelerated approval to lisocabtagene maraleucel (Breyanzi), a CD19-directed chimeric antigen receptor (CAR) T-cell therapy, for the treatment of adults with relapsed or refractory chronic lymphocytic leukemia (CLL) or small...
FDA Approves Tislelizumab for Previously Treated Patients With Advanced Esophageal Cancer
On March 14, the U.S. Food and Drug Administration (FDA) approved the humanized immunoglobulin G4 anti–PD-1 monoclonal antibody tislelizumab-jsgr (Tevimbra) as monotherapy for adults with unresectable or metastatic esophageal squamous cell carcinoma after prior systemic chemotherapy that did not...
Enfortumab Vedotin Plus Pembrolizumab Yields Benefit in Key Subgroups With Advanced Urothelial Cancer
The combination of the nectin-4–directed antibody-drug conjugate enfortumab vedotin-ejfv plus the PD-1 inhibitor pembrolizumab achieved favorable rates of progression-free survival, overall survival, and objective responses compared with chemotherapy among key subgroups of patients with previously...
p16-Positive Oropharyngeal Cancer: Surrogate Endpoints for Overall Survival in Clinical Trials
In a retrospective review reported in The Lancet Oncology, Gharzai et al identified intermediate clinical endpoints that may serve as surrogates for overall survival in trials assessing definitive treatment of patients with p16-positive oropharyngeal squamous cell carcinoma. Study Details The...
Trends in Breast Cancer Diagnoses During the COVID-19 Pandemic
Investigators may have identified a decrease in newly diagnosed breast cancer cases during the first year of the COVID-19 pandemic, according to a recent study published by Fefferman et al in Cancer Medicine. The findings highlight that breast cancer was not immune to pandemic-related stressors and ...
Previously Untreated Advanced Urothelial Cancer: Antibody-Drug Conjugate Plus PD-1 Inhibitor
As reported in The New England Journal of Medicine by Thomas Powles, MD, and colleagues, the phase III EV-302 trial has shown that the combination of the antibody-drug conjugate enfortumab vedotin-ejfv and the PD-1 inhibitor pembrolizumab improved progression-free and overall survival vs...
SABR in Patients With Early NSCLC and Interstitial Lung Disease
In a study reported in JAMA Oncology, David A. Palma, MD, PhD, and colleagues found that stereotactic ablative radiotherapy (SABR) met criteria for efficacy and toxicity in patients with early non–small cell lung cancer (NSCLC) and interstitial lung disease (ILD). As stated by the investigators,...
From a Small Town in Lebanon, a Young Doctor Follows His Passion to an International Career in Cancer Research
Philip A. Salem, MD, Director Emeritus of Cancer Research at St. Luke’s Episcopal Hospital, Houston, was born and reared in Bterram, a village that overlooks the Mediterranean Sea. “I had the most beautiful and blessed childhood, as I lived in a household dominated by a father who believed in the...
Nab-sirolimus in Advanced Malignant Perivascular Epithelioid Cell Tumors: AMPECT Trial Final Analysis
As reported in the Journal of Clinical Oncology by Wagner et al, final analysis of the phase II AMPECT trial has shown a median duration of response of more than 3 years in patients with advanced malignant perivascular epithelioid cell tumors treated with nab-sirolimus. The primary analysis of the...
ACS and Flatiron Health Announce Recipients of Fourth Annual Real-World Data Impact Awards
The American Cancer Society (ACS) and Flatiron Health announced the recipients of the 2023 Real-World Data Impact Awards, which will support clinically relevant research regarding the treatment of and outcomes for patients with cancer. 2023 marks the fourth year of the joint grant-making program,...
Novel Dual-Target CAR T-Cell Therapy for Recurrent Glioblastoma
Targeting two brain tumor–associated proteins with chimeric antigen receptor (CAR) T-cell therapy may reduce solid tumor growth in patients with recurrent glioblastoma, according to results from a phase I trial published by Bagley et al in Nature Medicine. The findings suggest that the new...
Germ Cell Tumors: Survival Rates in Female vs Male Patients
Female patients with ovarian germ cell tumors may have worse prognoses compared with male patients with testicular germ cell tumors, according to a recent study published by Sköld et al in the Journal of Internal Medicine. Background Both ovarian and testicular germ cell tumors predominantly...
Neoadjuvant Therapy for EGFR-Positive Lung Adenocarcinoma
This is Part 3 of Optimizing Outcomes for Patients With Locally Advanced and Metastatic NSCLC, a three-part video roundtable series. Scroll down to watch the other videos from this Roundtable. In this video, Drs. Melissa Johnson, Vamsidhar Velcheti, and Helena Yu discuss the neoadjuvant treatment ...
Management of Stage IIIA NSCLC in a Former Smoker
This is Part 2 of Optimizing Outcomes for Patients With Locally Advanced and Metastatic NSCLC, a three-part video roundtable series. Scroll down to watch the other videos from this Roundtable. In this video, Drs. Melissa Johnson, Vamsidhar Velcheti, and Helena Yu discuss the management of stage...
Locally Advanced NSCLC
This is Part 1 of Optimizing Outcomes for Patients With Locally Advanced and Metastatic NSCLC, a three-part video roundtable series. Scroll down to watch the other videos from this Roundtable. In this video, Drs. Melissa Johnson, Vamsidhar Velcheti, and Helena Yu discuss the management of locally ...
Cancer Prevalence in Europe as of 2020
In a study reported in The Lancet Oncology, De Angelis et al estimated the numbers of patients alive after a cancer diagnosis in Europe as of 2020. Study Details The study used data from the EUROCARE-6 study to estimate the prevalence of cancer in 29 European countries and the 27 countries in the ...
Metastatic Triple-Negative Breast Cancer: Sacituzumab Govitecan vs Single-Agent Chemotherapy in Previously Treated Patients
As reported in the Journal of Clinical Oncology by Aditya Bardia, MD, MPH, and colleagues, final results of the phase III ASCENT trial showed continued superior progression-free and overall survival with sacituzumab govitecan-hziy, an anti–trophoblast cell surface antigen 2 (Trop-2) antibody-drug...
Sunitinib in Metastatic Progressive Pheochromocytomas and Paragangliomas
In a phase II trial (FIRSTMAPPP) reported in The Lancet, Eric Baudin, MD, and colleagues found that the multikinase inhibitor sunitinib was active in patients with metastatic progressive pheochromocytomas and paragangliomas. As stated by the investigators, “No randomized controlled trial has ever...
